Component

Airway response to tartrazine in aspirin-intolerant asthmatics

Experimental model, exposure and limitations remain on each linked record.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Four of 156 aspirin-intolerant asthmatics had a double-blind-confirmed tartrazine response with more than a 25% FEV1 fall and symptoms.

    Experimental context and source evidence
    dose
    Increasing tartrazine doses up to 25 mg; positive open challenges repeated double blind
    duration
    Acute challenge; exact observation window not specified in abstract
    evidence_access
    Primary PubMed abstract; unrecovered method details explicitly retained.
    evidence_scope
    literature_reviewed; source-specific experimental curation
    experimental_model
    156 patients with confirmed aspirin-induced asthma in a multicenter study
    limitations
    Four confirmed reactions do not establish universal aspirin-tartrazine cross-reactivity or a shared IgE/COX mechanism. Results are specific to the recruited population.
    nutrient_topic
    Tartrazine food-colorant chapter; nutrient, drug and peptide interactions retain their models and limits. · Tartrazine
    organism
    156 patients with confirmed aspirin-induced asthma in a multicenter study
    plain_language
    Four of 156 aspirin-intolerant asthmatics had a double-blind-confirmed tartrazine response with more than a 25% FEV1 fall and symptoms.
    primary_references
    Intolerance to tartrazine in aspirin-induced asthma: results of a multicenter study. (1988). https://pubmed.ncbi.nlm.nih.gov/3387687/ DOI: 10.1159/000195391
    route
    Oral tartrazine; aspirin intolerance was a selection criterion, not co-administration
    tissue
    Oral challenge, spirometry and symptoms

    Tartrazine: mechanisms, molecular forms and cross-actor connections (2026-09-20) · lines 325–334

    Original AI-assisted curation of eighteen primary studies. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 156 patients with confirmed aspirin-induced asthma in a multicenter study · source_derived_draft · unverified_draft

    ## tartrazine-aspirin-asthma Four of 156 aspirin-intolerant asthmatics had a double-blind-confirmed tartrazine response with more than a 25% FEV1 fall and symptoms. Model/species: 156 patients with confirmed aspirin-induced asthma in a multicenter study Tissue: Oral challenge, spirometry and symptoms Exposure: Increasing tartrazine doses up to 25 mg; positive open challenges repeated double blind Route: Oral tartrazine; aspirin intolerance was a selection criterion, not co-administration Duration: Acute challenge; exact observation window not specified in abstract Limits: Four confirmed reactions do not establish universal aspirin-tartrazine cross-reactivity or a shared IgE/COX mechanism. Results are specific to the recruited population. Primary reference: Intolerance to tartrazine in aspirin-induced asthma: results of a multicenter study. (1988). https://pubmed.ncbi.nlm.nih.gov/3387687/ DOI: 10.1159/000195391 Access: Primary PubMed abstract; unrecovered method details explicitly retained.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards